Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 462 entries
Sorted by: Best Match Show Resources per page
Carcinomas of the head and neck.

Cancer treatment and research

[No authors listed]
PMID: 1976371
Cancer Treat Res. 1990;52:3-282.

No abstract available.

Cite
Carcinomas of the head and neck. Cancer Treat Res. 1990;52:3-282
(1990). Carcinomas of the head and neck. Cancer treatment and research, 523-282.
"Carcinomas of the head and neck." Cancer treatment and research vol. 52 (1990): 3-282.
Carcinomas of the head and neck. Cancer Treat Res. 1990;52:3-282. PMID: 1976371.
Copy Download .nbib Format: NLM
Palliative Care in Lung Cancer.

Cancer treatment and research

Shinde AM, Dashti A.
PMID: 27535397
Cancer Treat Res. 2016;170:225-50. doi: 10.1007/978-3-319-40389-2_11.

Lung cancer is the most common cancer worldwide and is the leading cause of cancer death for both men and women in the USA. Symptom burden in patients with advanced lung cancer is very high and has a negative...

Cite
Shinde AM, Dashti A. Palliative Care in Lung Cancer. Cancer Treat Res. 2016;170:225-50doi: 10.1007/978-3-319-40389-2_11.
Shinde, A. M., & Dashti, A. (2016). Palliative Care in Lung Cancer. Cancer treatment and research, 170225-50. https://doi.org/10.1007/978-3-319-40389-2_11
Shinde, Arvind M, and Dashti, Azadeh. "Palliative Care in Lung Cancer." Cancer treatment and research vol. 170 (2016): 225-50. doi: https://doi.org/10.1007/978-3-319-40389-2_11
Shinde AM, Dashti A. Palliative Care in Lung Cancer. Cancer Treat Res. 2016;170:225-50. doi: 10.1007/978-3-319-40389-2_11. PMID: 27535397.
Copy Download .nbib Format: NLM
Timing and sequencing of chemoradiotherapy.

Cancer treatment and research

Haraf DJ, Weichselbaum RR, Vokes EE.
PMID: 7779616
Cancer Treat Res. 1995;74:173-98. doi: 10.1007/978-1-4615-2023-8_10.

No abstract available.

Cite
Haraf DJ, Weichselbaum RR, Vokes EE. Timing and sequencing of chemoradiotherapy. Cancer Treat Res. 1995;74:173-98doi: 10.1007/978-1-4615-2023-8_10.
Haraf, D. J., Weichselbaum, R. R., & Vokes, E. E. (1995). Timing and sequencing of chemoradiotherapy. Cancer treatment and research, 74173-98. https://doi.org/10.1007/978-1-4615-2023-8_10
Haraf, D J, et al. "Timing and sequencing of chemoradiotherapy." Cancer treatment and research vol. 74 (1995): 173-98. doi: https://doi.org/10.1007/978-1-4615-2023-8_10
Haraf DJ, Weichselbaum RR, Vokes EE. Timing and sequencing of chemoradiotherapy. Cancer Treat Res. 1995;74:173-98. doi: 10.1007/978-1-4615-2023-8_10. PMID: 7779616.
Copy Download .nbib Format: NLM
Overview of head and neck cancer.

Cancer treatment and research

Masters G, Brockstein B.
PMID: 12619536
Cancer Treat Res. 2003;114:1-13. doi: 10.1007/0-306-48060-3_1.

No abstract available.

Cite
Masters G, Brockstein B. Overview of head and neck cancer. Cancer Treat Res. 2003;114:1-13doi: 10.1007/0-306-48060-3_1.
Masters, G., & Brockstein, B. (2003). Overview of head and neck cancer. Cancer treatment and research, 1141-13. https://doi.org/10.1007/0-306-48060-3_1
Masters, Gregory, and Brockstein, Bruce. "Overview of head and neck cancer." Cancer treatment and research vol. 114 (2003): 1-13. doi: https://doi.org/10.1007/0-306-48060-3_1
Masters G, Brockstein B. Overview of head and neck cancer. Cancer Treat Res. 2003;114:1-13. doi: 10.1007/0-306-48060-3_1. PMID: 12619536.
Copy Download .nbib Format: NLM
The role of palliative medicine in cancer patient care.

Cancer treatment and research

Mitchell WM, von Gunten CF.
PMID: 18283775
Cancer Treat Res. 2008;140:159-71. doi: 10.1007/978-0-387-73639-6_10.

No abstract available.

Cite
Mitchell WM, von Gunten CF. The role of palliative medicine in cancer patient care. Cancer Treat Res. 2008;140:159-71doi: 10.1007/978-0-387-73639-6_10.
Mitchell, W. M., & von Gunten, C. F. (2008). The role of palliative medicine in cancer patient care. Cancer treatment and research, 140159-71. https://doi.org/10.1007/978-0-387-73639-6_10
Mitchell, William M, and von Gunten, Charles F. "The role of palliative medicine in cancer patient care." Cancer treatment and research vol. 140 (2008): 159-71. doi: https://doi.org/10.1007/978-0-387-73639-6_10
Mitchell WM, von Gunten CF. The role of palliative medicine in cancer patient care. Cancer Treat Res. 2008;140:159-71. doi: 10.1007/978-0-387-73639-6_10. PMID: 18283775.
Copy Download .nbib Format: NLM
LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY.

Cancer treatment and research communications

Cannioto R, Etter JL, LaMonte MJ, Ray AD, Joseph JM, Al Qassim E, Eng KH, Moysich KB.
PMID: 29632898
Cancer Treat Res Commun. 2018;14:37-45. doi: 10.1016/j.ctarc.2018.01.001.

DISCUSSION/CONCLUSION: These data add to the body of evidence suggesting that physical inactivity is an independent risk and prognostic factor for cancer. Additional research utilizing prospectively collected data is needed to substantiate the current findings.

Cite
Cannioto R, Etter JL, LaMonte MJ, et al. LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY. Cancer Treat Res Commun. 2018;14:37-45doi: 10.1016/j.ctarc.2018.01.001.
Cannioto, R., Etter, J. L., LaMonte, M. J., Ray, A. D., Joseph, J. M., Al Qassim, E., Eng, K. H., & Moysich, K. B. (2018). LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY. Cancer treatment and research communications, 1437-45. https://doi.org/10.1016/j.ctarc.2018.01.001
Cannioto, Rikki, et al. "LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY." Cancer treatment and research communications vol. 14 (2018): 37-45. doi: https://doi.org/10.1016/j.ctarc.2018.01.001
Cannioto R, Etter JL, LaMonte MJ, Ray AD, Joseph JM, Al Qassim E, Eng KH, Moysich KB. LIFETIME PHYSICAL INACTIVITY IS ASSOCIATED WITH LUNG CANCER RISK AND MORTALITY. Cancer Treat Res Commun. 2018;14:37-45. doi: 10.1016/j.ctarc.2018.01.001. PMID: 29632898; PMCID: PMC5889080.
Copy Download .nbib Format: NLM
Relationship between anti-depressant use and lung cancer survival.

Cancer treatment and research communications

Zingone A, Brown D, Bowman ED, Vidal O, Sage J, Neal J, Ryan BM.
PMID: 28944316
Cancer Treat Res Commun. 2017;10:33-39. doi: 10.1016/j.ctarc.2017.01.001. Epub 2017 Jan 29.

OBJECTIVES: In recent years, the anti-cancer properties of several commonly used drugs have been explored, with drugs such as aspirin and beta-blockers associated with improved cancer outcomes. Previous preclinical work demonstrated that tricyclic anti-depressants have antitumor efficacy in lung...

Cite
Zingone A, Brown D, Bowman ED, et al. Relationship between anti-depressant use and lung cancer survival. Cancer Treat Res Commun. 2017;10:33-39doi: 10.1016/j.ctarc.2017.01.001.
Zingone, A., Brown, D., Bowman, E. D., Vidal, O., Sage, J., Neal, J., & Ryan, B. M. (2017). Relationship between anti-depressant use and lung cancer survival. Cancer treatment and research communications, 1033-39. https://doi.org/10.1016/j.ctarc.2017.01.001
Zingone, Adriana, et al. "Relationship between anti-depressant use and lung cancer survival." Cancer treatment and research communications vol. 10 (2017): 33-39. doi: https://doi.org/10.1016/j.ctarc.2017.01.001
Zingone A, Brown D, Bowman ED, Vidal O, Sage J, Neal J, Ryan BM. Relationship between anti-depressant use and lung cancer survival. Cancer Treat Res Commun. 2017;10:33-39. doi: 10.1016/j.ctarc.2017.01.001. Epub 2017 Jan 29. PMID: 28944316; PMCID: PMC5603309.
Copy Download .nbib Format: NLM
Head and Neck Cancer-The Patient Perspective.

Cancer treatment and research

Lapiduss S, Bartoccini F.
PMID: 29435833
Cancer Treat Res. 2018;174:1-16. doi: 10.1007/978-3-319-65421-8_1.

The following chapter details diagnosis, treatment, and aftermath from a head and neck cancer patient's point of view. It illustrates the potential daily challenges of undergoing treatment while coping with the diagnosis of cancer. The toxicities of treatment and...

Cite
Lapiduss S, Bartoccini F. Head and Neck Cancer-The Patient Perspective. Cancer Treat Res. 2018;174:1-16doi: 10.1007/978-3-319-65421-8_1.
Lapiduss, S., & Bartoccini, F. (2018). Head and Neck Cancer-The Patient Perspective. Cancer treatment and research, 1741-16. https://doi.org/10.1007/978-3-319-65421-8_1
Lapiduss, Sally, and Bartoccini, Francesca. "Head and Neck Cancer-The Patient Perspective." Cancer treatment and research vol. 174 (2018): 1-16. doi: https://doi.org/10.1007/978-3-319-65421-8_1
Lapiduss S, Bartoccini F. Head and Neck Cancer-The Patient Perspective. Cancer Treat Res. 2018;174:1-16. doi: 10.1007/978-3-319-65421-8_1. PMID: 29435833.
Copy Download .nbib Format: NLM
Comparative effectiveness issues in lung cancer.

Cancer treatment and research

Varghese TK.
PMID: 25677021
Cancer Treat Res. 2015;164:101-19. doi: 10.1007/978-3-319-12553-4_7.

Lung cancer accounts for more cancer deaths than breast, prostate, colorectal and pancreatic cancer combined. With an aging population, greater intensity of cancer care, and the need for care of the growing number of cancer survivors, comparative effectiveness research...

Cite
Varghese TK. Comparative effectiveness issues in lung cancer. Cancer Treat Res. 2015;164:101-19doi: 10.1007/978-3-319-12553-4_7.
Varghese, T. K. (2015). Comparative effectiveness issues in lung cancer. Cancer treatment and research, 164101-19. https://doi.org/10.1007/978-3-319-12553-4_7
Varghese, Thomas K. "Comparative effectiveness issues in lung cancer." Cancer treatment and research vol. 164 (2015): 101-19. doi: https://doi.org/10.1007/978-3-319-12553-4_7
Varghese TK. Comparative effectiveness issues in lung cancer. Cancer Treat Res. 2015;164:101-19. doi: 10.1007/978-3-319-12553-4_7. PMID: 25677021.
Copy Download .nbib Format: NLM
Examining Lung Cancer Screening Behaviors in the Primary Care Setting: A Mixed Methods Approach.

Journal of cancer treatment and research

Ahsan A, Zimmerman E, Rodriguez EM, Widman C, Erwin DO, Saad-Harfouche FG, Mahoney MC.
PMID: 31179379
J Cancer Treat Res. 2019 Mar;7(1):1-8. doi: 10.11648/j.jctr.20190701.11. Epub 2019 Mar 11.

While the National Lung Screening Trials (NLST) demonstrated the efficacy of low dose chest computed tomography (LDCT) for lung cancer early detection, utilization of LDCT remains suboptimal. The purpose of this formative study was to understand attitudes and beliefs...

Cite
Ahsan A, Zimmerman E, Rodriguez EM, et al. Examining Lung Cancer Screening Behaviors in the Primary Care Setting: A Mixed Methods Approach. J Cancer Treat Res. 2019;7(1):1-8doi: 10.11648/j.jctr.20190701.11.
Ahsan, A., Zimmerman, E., Rodriguez, E. M., Widman, C., Erwin, D. O., Saad-Harfouche, F. G., & Mahoney, M. C. (2019). Examining Lung Cancer Screening Behaviors in the Primary Care Setting: A Mixed Methods Approach. Journal of cancer treatment and research, 7(1), 1-8. https://doi.org/10.11648/j.jctr.20190701.11
Ahsan, Alvie, et al. "Examining Lung Cancer Screening Behaviors in the Primary Care Setting: A Mixed Methods Approach." Journal of cancer treatment and research vol. 7,1 (2019): 1-8. doi: https://doi.org/10.11648/j.jctr.20190701.11
Ahsan A, Zimmerman E, Rodriguez EM, Widman C, Erwin DO, Saad-Harfouche FG, Mahoney MC. Examining Lung Cancer Screening Behaviors in the Primary Care Setting: A Mixed Methods Approach. J Cancer Treat Res. 2019 Mar;7(1):1-8. doi: 10.11648/j.jctr.20190701.11. Epub 2019 Mar 11. PMID: 31179379; PMCID: PMC6554719.
Copy Download .nbib Format: NLM
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.

Cancer treatment and research communications

Calvo E, Spira A, Miguel M, Kondo S, Gazzah A, Millward M, Prenen H, Rottey S, Warburton L, Alanko T, Cassier PA, Yoh K, Italiano A, Moreno V, Peltola K, Seto T, Toyozawa R, Afar DE, Englert S, Komarnitsky P, Lambert S, Parikh A, Vosganian G, Gao B.
PMID: 34329846
Cancer Treat Res Commun. 2021;28:100405. doi: 10.1016/j.ctarc.2021.100405. Epub 2021 May 25.

BACKGROUND: Agents targeting programmed cell death protein 1 (PD-1) have been approved as monotherapy for patients with small cell lung cancer (SCLC). In preclinical models, the combined targeting of PD-1 and delta-like protein 3 resulted in enhanced antitumor activity....

Cite
Calvo E, Spira A, Miguel M, et al. Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. Cancer Treat Res Commun. 2021;28:100405doi: 10.1016/j.ctarc.2021.100405.
Calvo, E., Spira, A., Miguel, M., Kondo, S., Gazzah, A., Millward, M., Prenen, H., Rottey, S., Warburton, L., Alanko, T., Cassier, P. A., Yoh, K., Italiano, A., Moreno, V., Peltola, K., Seto, T., Toyozawa, R., Afar, D. E., Englert, S., Komarnitsky, P., Lambert, S., Parikh, A., Vosganian, G., & Gao, B. (2021). Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. Cancer treatment and research communications, 28100405. https://doi.org/10.1016/j.ctarc.2021.100405
Calvo, Emiliano, et al. "Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer." Cancer treatment and research communications vol. 28 (2021): 100405. doi: https://doi.org/10.1016/j.ctarc.2021.100405
Calvo E, Spira A, Miguel M, Kondo S, Gazzah A, Millward M, Prenen H, Rottey S, Warburton L, Alanko T, Cassier PA, Yoh K, Italiano A, Moreno V, Peltola K, Seto T, Toyozawa R, Afar DE, Englert S, Komarnitsky P, Lambert S, Parikh A, Vosganian G, Gao B. Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. Cancer Treat Res Commun. 2021;28:100405. doi: 10.1016/j.ctarc.2021.100405. Epub 2021 May 25. PMID: 34329846.
Copy Download .nbib Format: NLM
The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial.

Cancer treatment and research communications

Wang J, Yu X, Barnes G, Leaw S, Bao Y, Tang B.
PMID: 34952253
Cancer Treat Res Commun. 2021 Dec 17;30:100501. doi: 10.1016/j.ctarc.2021.100501. Epub 2021 Dec 17.

BACKGROUND: This study assessed the effects of adding tislelizumab to first-line standard-of- care chemotherapy on the health-related quality of life (HRQoL) of patients with advanced squamous non-small cell lung cancer (sq-NSCLC).PATIENTS AND METHODS: Patients in this open-label, multicenter, phase...

Cite
Wang J, Yu X, Barnes G, et al. The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer Treat Res Commun. 2021;30:100501doi: 10.1016/j.ctarc.2021.100501.
Wang, J., Yu, X., Barnes, G., Leaw, S., Bao, Y., & Tang, B. (2021). The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer treatment and research communications, 30100501. https://doi.org/10.1016/j.ctarc.2021.100501
Wang, J, et al. "The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial." Cancer treatment and research communications vol. 30 (2021): 100501. doi: https://doi.org/10.1016/j.ctarc.2021.100501
Wang J, Yu X, Barnes G, Leaw S, Bao Y, Tang B. The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer Treat Res Commun. 2021 Dec 17;30:100501. doi: 10.1016/j.ctarc.2021.100501. Epub 2021 Dec 17. PMID: 34952253.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 462 entries